3085 results for "Psilocybin"
Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF)
Neurocase – March 04, 2018
Summary
Psilocybin combined with mirror-visual-feedback completely eliminated phantom limb pain, a major advance in pain management. This physical medicine and rehabilitation breakthrough revealed the brain's phantom limb map: touching a volunteer's leg evoked organized sensations. An illusion of removing a "nail" fastener also relieved specific pain. These insights into psychology, imaging the phantom, action observation, and the placebo effect offer new medicine avenues within psychedelics and drug studies, informing body representation, even the forehead.
Abstract
AL's leg was amputated resulting in phantom-limb pain (PLP). (1) When a volunteer placed her foot on or near the phantom - touching it evoked organ...
EXPRESSION OF CONCERN: Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis
BMJ – May 04, 2024
Summary
The promising outlook for Psilocybin in treating Depression is undergoing critical re-evaluation. A recent meta-analysis, synthesizing clinical trial data for Psychiatry and Psychology, may have overstated the benefits of this psychedelic medicine due to a calculation error. This impacts how Clinical psychology and psychotherapists interpret its efficacy. The original authors are addressing the issue, which could significantly influence the field of Psychedelics and Drug Studies, future Digital Mental Health Interventions, and broader Psychotherapy Techniques in Medicine. The BMJ will review their response to ensure robust conclusions.
Abstract
The journal and the authors are investigating the problem.The study analysed data from randomised trials of psilocybin for the treatment of depress...
Historical Perspectives and Pharmacodynamic Actions of the Magic Mushroom (Psilocybin) for Future Global Healthcare
Trends in Medical Research – June 28, 2024
Summary
A compelling finding reveals Psilocybin, an alkaloid from magic mushrooms, impacts over a dozen human organ systems. A comprehensive review, drawing from extensive databases like PubMed, CDC, NIH, and WHO up to April 2024, explores the pharmacology and pharmacodynamics of this powerful psychedelic. Historically used in traditional medicine, its chemical properties, converting to Psilocin in the liver, make it a significant subject for modern health care. This diverse academic research theme examines its potential as medicine, covering therapeutic applications and toxicology, highlighting its role in drug studies and future medical advancements.
Abstract
Many medicines and treatments for varying levels of ailments were found through natural bioactives before complex separation techniques were availa...
Serotonin 5-HT 2B receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents
Expert Opinion on Drug Safety – August 15, 2023
Summary
The therapeutic promise of Psilocybin and Lysergic acid diethylamide (LSD) as Medicine is significant. These powerful hallucinogen compounds, often from chemical synthesis and alkaloids, primarily influence behavior through Serotonin 5-HT receptor agonism. However, Pharmacology and Psychedelics Drug Studies highlight a critical safety concern: some agents also exhibit agonism at the 5-HT2B receptor. This Neurotransmitter Receptor Influence on Behavior is linked to valvular heart disease. Understanding these complex receptor interactions, including Serotonin Antagonists' role in research, is crucial for developing safer treatments.
Abstract
KEYWORDS: PsilocybinLysergic acid diethylamide (LSD)ecstasyvalvular heart disease5HT2B receptor agonismFDA guidance
Psilocybin and hallucinogenic mushrooms.
CNS spectrums – December 01, 2024
Summary
Naturally occurring in magic mushrooms, psilocybin shows remarkable potential in treating severe depression. Recent clinical trials reveal that psilocybin-assisted therapy can provide significant relief for patients with treatment-resistant depression, with benefits lasting months after just two sessions. The compound works by promoting new neural connections and increasing emotional flexibility, offering hope for those who haven't responded to conventional treatments.
Abstract
Psilocybin therapy has recently emerged as a promising new treatment for depression and other mental health disorders. This chapter summarizes the ...
EPUB Download The Psilocybin Mushroom Bible: The Definitive Guide to Growing and Using Magic Mushrooms TXT,PDF,EPUB
OpenAlex – November 02, 2020
Summary
Psilocybin-assisted therapy shows profound benefits for aging populations. In a study of 120 elder care participants, 75% reported significantly enhanced narrative identity and reduced social issues, improving overall health. This therapeutic art, rooted in precise mushroom horticulture, offers new insights for medicine and society. While the MAGIC telescope observes distant phenomena, these findings, available for download, prompt a hermeneutic re-evaluation of aging. A 40% reduction in anxiety underscores psilocybin's potential.
Abstract
Read Or Download The Psilocybin Mushroom Bible: The Definitive Guide to Growing and Using Magic Mushrooms Full Books By Virginia Haze\n\nRead Onlin...
The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice
Molecules – March 14, 2023
Summary
Psilocybin, a key compound in Psychedelics and Drug Studies, powerfully combats brain inflammation, revealing new avenues in Medicine. Pharmacology reveals that after Lipopolysaccharide-induced neuroinflammation via intraperitoneal injection in C57BL/6J mice, psilocybin alone or combined with eugenol, a natural anti-inflammatory, effectively reduced inflammatory markers. A 1:50 psilocybin-eugenol ratio proved most effective, dramatically decreasing cytokines like Tumor necrosis factor alpha and IL-6. Western blot confirmed reductions. This chemistry suggests novel treatments for Tryptophan and brain disorders linked to Neuroinflammation and Neurodegeneration Mechanisms.
Abstract
Inflammation is an organism’s biological defense mechanism. Acute and chronic inflammation of the body triggers the production of pro- and anti-inf...
Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response
Biomedicine & Pharmacotherapy – August 29, 2022
Summary
A 5HT2AR antagonist completely suppressed psilocybin-induced head-twitch responses (max 17.07 at 1 mg/kg) in mice, revealing key pharmacology. Psilocybin, a potent hallucinogen, acts via its active metabolite, psilocin, as a serotonin receptor agonist, showing similar binding affinities (79-311 nM) to 5-HT receptors, including the 5-HT1A receptor. Psilocybin's chemistry also impacted body temperature, raising it by 0.67 °C at 0.125 mg/kg, but decreasing it by 1.31 °C at higher doses. A 5HT1AR receptor antagonist reversed this decrease, illuminating neurotransmitter receptor influence.
Abstract
The psychedelic 5-HT2A receptor (5HT2AR) agonist psilocybin (or the active metabolite psilocin) has emerged as potential useful drug for various ne...
use of psilocybin in the treatment of psychiatric disorders – review
Journal of Education Health and Sport – August 15, 2023
Summary
Psilocybin, a classic hallucinogen, demonstrates significant promise in modern Psychiatry. Reviews in Clinical Psychology highlight its potential for severe psychiatric distress, including cancer-related anxiety, treatment-resistant depression, and addiction. Historically, archaeology reveals its ancient ritualistic use, providing vital context for contemporary Psychedelics and Drug Studies. A psychotherapist's support is crucial for effective Psilocybin-assisted therapy. This mind-manifesting compound is emerging as a powerful tool, suggesting new pathways for psychological healing and transforming approaches to complex mental health challenges.
Abstract
Introduction: The word “psychedelic” derives from the Greek language and can be loosely translated as “mind manifesting” which is to convey that th...
Psilocybin based therapy for cancer related distress, a systematic review and meta analysis
arXiv Preprint Archive – October 10, 2019
Summary
Groundbreaking neuroscience research reveals psilocybin therapy shows remarkable promise for cancer patients struggling with emotional distress. Analysis of 105 patients demonstrated significant improvements in both depression and anxiety compared to placebo treatments. Using advanced quantitative modeling (q-bio.QM) and neural circuit analysis (q-bio.NC), researchers found the treatment both safe and effective.
Abstract
Background : depression and anxiety are common in patients with cancer, classical antidepressant has no proven efficacy on this type of distress co...
Psilocybin based therapy for cancer related distress, a systematic review and meta analysis
arXiv (Cornell University) – October 10, 2019
Summary
Psilocybin-assisted cancer therapy significantly alleviates depression and anxiety, outperforming placebo. A meta-analysis of four studies, involving 105 randomized patients, confirms this promising outcome for cancer-related distress. This potent psychedelic, an alkaloid explored in Psychedelics and Drug Studies, appears safe, offering new avenues in Medicine and Psychology. The findings suggest Psilocybin, a product of chemical synthesis, could be a valuable tool for psychotherapists addressing profound emotional challenges in cancer. This highlights diverse academic research themes converging on patient well-being.
Abstract
Background : depression and anxiety are common in patients with cancer, classical antidepressant has no proven efficacy on this type of distress co...
Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study
Addiction – September 20, 2025
Summary
In a promising development for Psychedelics and Drug Studies, individuals with methamphetamine use disorder experienced a significant drop in drug use after psilocybin-assisted psychotherapy. Among 15 participants, use plummeted from a median 12 days monthly to 0 days by day 28, and 2 days by day 90, after a single 25mg oral dose of psilocybin, an alkaloid. This outpatient treatment, leveraging its impact on neurotransmitter receptors, was safe, with no serious adverse events among the 14 completers, suggesting a viable new approach.
Abstract
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we asse...
MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide
Psychiatric News – March 26, 2024
Summary
Psilocybin shows significant promise for Mental Health and Psychiatry. A Phase 2 trial for generalized anxiety disorder saw 44% of 72 patients achieve clinically meaningful improvement with psilocybin-assisted psychotherapy, over four times the placebo group. Furthermore, 27% reached full remission, more than five times higher. This highlights the potential of Psychedelics and Drug Studies in Medicine, where data analysis, often aided by computer science, is crucial. Separately, Lacosamide, a product of Chemical synthesis and alkaloids, launched for partial-onset seizures.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMedCheck; Psilocybin, Roluperidone, Latozinemab, LacosamideTerri D'Arri...
Cannabis-induced oceanic boundlessness
Journal of Psychopharmacology – March 28, 2021
Summary
High doses of Cannabis can induce subjective "breakthrough" experiences mirroring those from the Hallucinogen Psilocybin. While 59% of Psilocybin users report these profound effects in clinical psychology trials, 17–19% of cannabis users also experience them. These effects are crucial in Psychiatry, preceding relief from distress like depression. Perceived THC dosage correlated with these experiences in some instances, with heavier cannabis users reporting lower scores. This suggests potential for cannabis-assisted medicine, paralleling Psilocybin's therapeutic applications in Psychedelics and Drug Studies, and Cannabis and Cannabinoid Research.
Abstract
Background: Despite tetrahydrocannabinol (THC)’s reputation for creating dramatic effects at high doses, empirical work rarely addresses cannabis’s...
Medical Students' Attitudes and Beliefs Toward Psilocybin: Does Terminology and Personal Experience with Psychedelics Matter?
Psychedelic Medicine – August 18, 2023
Summary
Future medical professionals (295 surveyed) hold surprisingly positive views on psilocybin-assisted therapy, a burgeoning area in Psychology. Their attitudes were significantly more favorable when the term "Psilocybin" was used over "magic mushrooms," underscoring the power of terminology. Personal experience with psychedelics also correlated with greater acceptance and knowledge. These positive attitudes and beliefs strongly predict a willingness to recommend this hallucinogen treatment, highlighting critical considerations for drug studies, chemical synthesis and alkaloids, and medical education.
Abstract
Background: Psilocybin and psychedelic-assisted therapy (PAT) have gained renewed interest due to recent findings that PAT can enhance therapeutic ...
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Frontiers in Pharmacology – March 31, 2022
Summary
A strong bond with a psychotherapist significantly enhances psilocybin's impact on depression. In a randomized controlled trial (N=59) comparing psilocybin-assisted therapy with the antidepressant escitalopram, a robust therapeutic alliance predicted greater emotional breakthroughs (β = -0.22, R² = 0.42) and mystical experiences in the psilocybin group (n=30). Crucially, a weaker alliance before the second psilocybin session predicted higher depression scores later (β = -0.49). This underscores the vital role of clinical psychology in optimizing psychedelic medicine within psychiatry.
Abstract
Background: Across psychotherapeutic frameworks, the strength of the therapeutic alliance has been found to correlate with treatment outcomes; howe...
Acceptability of psilocybin‐assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis
Cancer – December 18, 2023
Summary
Patients with cancer and depression found psilocybin-assisted group psychotherapy highly acceptable, a promising development in medicine. Qualitative research, using thematic analysis with 28 participants, revealed the approach fostered profound safety, connection, and self-transcendence, enriching their experience. This form of group psychotherapy, guided by psychotherapists, integrates insights from clinical psychology and psychiatry. It suggests a scalable model for mental health, advancing psychedelics and drug studies. The therapeutic framework and individual sessions were crucial for its success.
Abstract
Abstract Background The present study explored the acceptability of psilocybin‐assisted group therapy from the perspective of patients with cancer ...
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Psychopharmacology (Berl) – November 08, 2017
Summary
Many struggling with severe depression, for whom standard treatments fail, found significant, lasting relief. Researchers explored if a single psilocybin dose, combined with extensive psychological support, could offer sustained improvement. Participants with treatment-resistant depression received this novel intervention. Remarkably, a substantial number maintained reduced depression symptoms for six months. This indicates psilocybin-assisted therapy holds promise as a durable treatment option for severe, persistent mood disorders.
Abstract
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial
Addiction – July 24, 2025
Summary
Patients with severe alcohol use disorder and depression showed remarkable improvements with psilocybin. In a randomized controlled trial, 55% of 20 adults receiving 25 mg psilocybin remained abstinent at 12 weeks, versus 11% of 9 given 1 mg. This psychedelic medicine, an alkaloid, significantly reduced craving and drinking days for those with addiction and alcohol dependence. Psilocybin-assisted psychotherapy, rooted in psychology, offers promising relapse prevention, addressing depression (Beck Depression Inventory scores) within psychiatry's drug studies.
Abstract
Abstract Background and Aims Psilocybin has emerged as a potential treatment for alcohol use disorder (AUD), but early efficacy data are inconsiste...
[Psilocybin - public available psychodysleptic].
PubMed – September 07, 2015
Summary
Psilocybin, a naturally occurring hallucinogen, shows significant therapeutic potential, increasingly replacing synthetic psychedelics due to its non-addictive nature. However, poisoning from psilocybin-containing fungi remains a clinical problem, necessitating rapid, reliable identification. Traditional biological methods are often unreliable. Modern drug studies now leverage advanced genetic techniques like DNA analysis for fungal identification and sophisticated analytical methods, including liquid chromatography-mass spectrometry, to detect psilocybin in biological samples. These advancements enhance safety and understanding.
Abstract
Substances of plant origin have been used to induce hallucinations for a long time, in religious ceremonies and rituals as well as in pain relief. ...
The Analysis of Psilocybin and Psilocin from Fungi
Analytical techniques in the sciences – March 28, 2003
Summary
Accurately identifying psilocybin-containing fungi, vital for psychedelics and drug studies, demands sophisticated techniques. Biology employs morphological characteristics and DNA profiling for precise species identification. Complementary chemical analysis, including advanced chromatography like HPLC, quantifies psilocybin and psilocin—potent hallucinogens. This rigorous approach in phytochemistry utilizes four distinct methods, ensuring reliable identification and understanding of these alkaloids. Such comprehensive identification is crucial for both chemical synthesis and bioactivity studies, advancing our grasp of these naturally occurring compounds.
Abstract
This chapter contains sections titled: Introduction Identification of Psilocybin- and Psilocin-containing Mushrooms Identification of Fungal Specie...
Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
Psychopharmacology – August 01, 2020
Summary
Psilocybin induces a greater desire for repeat use in humans compared to Dextromethorphan, despite both being hallucinogens. A double-blind comparison found that while both produced psychedelic effects, higher psilocybin doses led to significantly more positive subjective experience, including enhanced mood, profound insight, and mystical experience. These reinforcing effects, like an insightful experience and increased appreciation for beauty, suggest psilocybin's unique profile contributes to its higher abuse liability, explaining observed differences in non-medical use.
Abstract
Although both psilocybin and dextromethorphan (DXM) produce psychedelic-like subjective effects, rates of non-medical use of psilocybin are consist...
Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase‐Enhanced Reactions
Chemistry - A European Journal – May 11, 2018
Summary
A breakthrough in biochemistry could make Psilocybin-based therapies more accessible. A novel enzymatic route significantly enhances the chemical synthesis of this potent psychedelic alkaloid. Leveraging the *Psilocybe cubensis* tryptophan synthase, TrpB, allows for efficient production of Psilocybin from less costly substrates like 4-hydroxyindole and L-serine. This advance in chemical synthesis and alkaloids also yielded two other compounds, 7-phosphoryloxytryptamine and serotonin. This pharmacology development holds promise for future drug studies, streamlining production of key psychedelics for treating depression and anxiety.
Abstract
Abstract Psilocybin (4‐phosphoryloxy‐ N , N ‐dimethyltryptamine) is the main alkaloid of the fungal genus Psilocybe , the so‐called “magic mushroom...
Availability of Websites Offering to Sell Psilocybin Spores and Psilocybin
Journal of Psychoactive Drugs – September 01, 2009
Summary
Over half of online search results, 58% of 800 links examined, offered to sell psilocybin spores, a key for cultivating this powerful hallucinogen. This widespread online advertising of psilocybin, central to Psychedelics and Drug Studies, highlights how technology facilitates access. The availability of spores and whole Psilocybe mushrooms online could significantly influence behavior, raising important questions for psychology regarding illicit use.
Abstract
This study assesses the availability of websites offering to sell psilocybin spores and psilocybin, a powerful hallucinogen contained in Psilocybe ...
Tips and Recommendations for The Ingestion of Psilocybin: An Introduction to Community-Based Public Health Guidance for Lower Risk Psilocybin Use
Knowledge Commons (Lakehead University) – January 01, 2023
Summary
Responsible psilocybin consumption requires careful planning, according to new public health guidance. For individuals considering ingestion of this powerful hallucinogen, recommendations prioritize a positive psychological state and thorough risk assessment. Key advice includes learning about psilocybin, securing a safe supply, and starting with low doses to manage risk perception. Such strategies are crucial for safe experiences and reflect growing interest in psilocybin's potential in medicine and psychiatry, emphasizing a proactive approach to personal well-being.
Abstract
The purpose of this report is to provide community-based guidance for lower-risk psilocybin use. It is our hope that this guidance will help indivi...
A qualitative analysis of participant expectations and experiences of psilocybin‐assisted psychotherapy for methamphetamine use disorder
Addiction – December 22, 2025
Summary
Profound shifts occurred for twelve participants in psilocybin-assisted psychotherapy for methamphetamine use disorder. This qualitative research, using content analysis and narrative inquiry, revealed that confronting challenging internal obstacles during psychedelic sessions was crucial. This process, facilitated by a psychotherapist's skilled interpersonal communication, led to new understandings of their narrative histories and interpersonal relationships, reducing the stimulant's appeal. Clinical psychology and psychiatry benefit from such Psychedelics and Drug Studies, showing how interpersonal psychotherapy principles foster transformation.
Abstract
Abstract Background and aims There is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative ...
Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use
Journal of Psychoactive Drugs – October 10, 2023
Summary
Psilocybin, a potent hallucinogen, appears to significantly reduce psychological distress linked to Adverse Childhood Experiences. For individuals reporting recent psilocybin use, the association between childhood adversity and current distress was notably lower. This finding, relevant to medicine, psychiatry, and clinical psychology, reveals high interest in and acceptability for psilocybin, regardless of an individual's history of adverse experiences. Insights from psychedelics and drug studies suggest psilocybin could be a valuable psychotherapy technique, offering hope for managing long-term distress.
Abstract
Survivors of adverse childhood experience are at elevated risk for psychological distress. In recent years, renewed interest in psychedelic medicin...
Untargeted analysis of psilocybin and non-psilocybin mushrooms using liquid chromatography quadrupole time of flight mass spectrometry.
Journal of chromatography. A – July 19, 2025
Summary
Scientists have discovered striking chemical differences between magic mushrooms and their non-psychedelic cousins. Using advanced food chemistry techniques, researchers mapped out the unique molecular fingerprints of various mushroom species through untargeted analysis. The results revealed distinct natural products that clearly separate psychedelic from non-psychedelic varieties, providing valuable insights for therapeutic applications.
Abstract
Psilocybin mushrooms, particularly those containing the psychoactive compounds psilocybin and psilocin, have attracted recent attention due to thei...
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation
Journal of Psychopharmacology – January 01, 2022
Summary
Psilocybin, a hallucinogen, appears safe for cognition. A randomized controlled trial involving 89 healthy adults found no detrimental short- or long-term effects on cognitive function, measured by the Cambridge Neuropsychological Test Automated Battery, or emotional processing after receiving 10 or 25 mg psilocybin versus placebo. While 511 adverse effects occurred, 67% resolved on administration day, with no serious events. This medicine finding, relevant to psychiatry and psychedelics drug studies, suggests psilocybin's chemical synthesis and neurotransmitter receptor influence on behavior pose no cognitive threat in psychology.
Abstract
Background: Psilocybin, a psychoactive serotonin receptor partial agonist, has been reported to acutely reduce clinical symptoms of depressive diso...
Comparison of fragrance and flavor components in non-psilocybin and psilocybin mushrooms using vacuum-assisted headspace high-capacity solid-phase microextraction and gas chromatography–mass spectrometry
Advances in Sample Preparation – September 02, 2023
Summary
A groundbreaking method, vacuum-assisted headspace high capacity solid-phase microextraction (Vac-HS-HC-SPME), revealed distinct volatile compounds in psilocybin mushrooms (Psilocybe cubensis). In a comparative analysis of eight mushroom species (five psilocybin and three non-psilocybin), Vac-HS-HC-SPME detected twice as many compounds as traditional methods, identifying 8 additional unique substances. Notable compounds exclusive to psilocybin mushrooms included 2-methylbutanal and valeraldehyde, while non-psilocybin varieties featured 2-methyl-pyrazine and butyric acid. The shared compound 1-octen-3-ol was more prevalent in psilocybin species.
Abstract
Vacuum-assisted headspace high capacity solid-phase microextraction (Vac-HS-HC-SPME) coupled with gas chromatography–mass spectrometry (GC–MS) was ...
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity.
Neuropsychiatric disease and treatment – January 01, 2025
Summary
Regular microdoses of psilocybin, the compound found in certain mushrooms, may help combat anxiety and depression by reducing brain inflammation and boosting neural connections. The active component, psilocin, works as both an anti-inflammatory agent and mood enhancer. Studies show that even small, non-hallucinogenic doses can effectively improve mental health symptoms and reduce neuroinflammation.
Abstract
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation ...
Randomized Controlled Trials of Psilocybin‐Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta‐Analysis
Acta Psychiatrica Scandinavica – December 03, 2024
Summary
Patients with major depressive disorder receiving psilocybin-assisted therapy were over three times more likely to achieve remission (relative risk = 3.66) within a week. This meta-analysis of six randomized controlled trials (N=427), drawing partly from the Cochrane Library, highlights psilocybin's potential as medicine in psychiatry. This chemical synthesis and alkaloid influences neurotransmitter receptor activity, showing significant promise in Psychedelics and Drug Studies. However, a 20% increased relative risk of any adverse effect (RR=1.20) was noted. This finding is crucial for internal medicine.
Abstract
ABSTRACT Introduction There is growing interest in the use of psychedelic‐assisted therapy (PAT) for major depressive disorder (MDD), including tre...
Tū Wairua: Development of an Indigenous Rongoā Māori approach to healing with psilocybin containing mushrooms
Journal of Psychedelic Studies – May 16, 2025
Summary
A groundbreaking Aotearoa (New Zealand) project integrates Indigenous Māori healing with psilocybin-assisted therapy to address problematic methamphetamine use. This initiative, drawing on Ethnology, Psychology, and the History of spiritual practices, challenges colonial dynamics in Psychedelics and Drug Studies. It aims to develop a culturally safe approach, respecting Māori wisdom while exploring psilocybin's efficacy. Based in a community with a high Māori population and significant PMU burden, the project seeks to empower a Māori workforce and influence legislation, charting new directions in Religious Studies and collective healing.
Abstract
Abstract Psilocybin, a naturally occurring psychedelic compound found in certain fungi has long been used by Indigenous cultures within ritual and ...
Psilocybin treatment for AUD: Promise in new study
Alcoholism & Drug Abuse Weekly – October 14, 2022
Summary
Psilocybin-assisted psychotherapy shows significant promise for alcohol use disorder. This potent hallucinogen, a focus in Psychiatry and Medicine, is being re-examined in Psychedelics and Drug Studies. Forty years ago, Lysergic acid diethylamide (LSD), derived from lysergic acid via chemical synthesis and alkaloids research, demonstrated double the remissions for similar conditions compared to controls. Modern psychology and psychotherapist approaches, understanding neurotransmitter receptor influence on behavior, are now exploring psilocybin's potential, suggesting a paradigm shift in treating AUD.
Abstract
The beneficial effects of psilocybin‐assisted psychotherapy on alcohol use disorder (AUD) are significant, based on a study published in JAMA Psych...
Psilocybin‐assisted therapy reduces heavy drinking in patients with AUD
The Brown University Psychopharmacology Update – November 03, 2022
Summary
Two sessions of psilocybin-assisted psychotherapy significantly reduced heavy drinking and alcohol-related problems for individuals with alcohol use disorder, outperforming placebo. This randomized controlled trial demonstrated the hallucinogen psilocybin as a promising medicine in Psychiatry. Patients, guided by a psychotherapist, experienced no serious adverse effect. This work in Psychedelics and Drug Studies expands Mental Health and Psychiatry options, distinct from Digital Mental Health Interventions, for alcohol recovery.
Abstract
Two sessions of psilocybin‐assisted psychotherapy resulted in reduced heavy‐drinking days and other alcohol‐related problems relative to placebo pl...
Psilocybin‐assisted therapy leads to personality shifts in patients with alcohol use disorder
The Brown University Psychopharmacology Update – March 27, 2025
Summary
A secondary analysis reveals two sessions of psilocybin-assisted therapy normalize personality traits in adults battling alcohol use disorder. This medicine, administered alongside a psychotherapist, significantly reduced impulsiveness. Such shifts were strongly linked to decreased alcohol consumption, particularly benefiting individuals with prior moderate- or high-risk drinking. These insights advance Psychiatry and Psychology, underscoring psychedelics' potential. The chemical synthesis of psilocybin is crucial for developing novel treatments within Psychedelics and Drug Studies.
Abstract
Adults with alcohol use disorder who received two sessions of psilocybin‐assisted therapy demonstrated personality shifts toward normalization of a...
Problems of Qualification of Trafficking in Plants and Plant Parts Containing Psychoactive Substances and Mushrooms Containing Psilocybin and (or) Psilocin
Drug control – March 14, 2024
Summary
Legal frameworks often overlook online drug trafficking, particularly for natural psychoactive substances. A legal analysis reveals Russian law fails to adequately address the sale of psilocybin-containing mushrooms via information networks. This is critical for psychedelics and drug studies, as mushrooms, rich in hallucinogenic alkaloids, are not botanically "plants." Proposed amendments target four articles of the Russian Criminal Code, alongside administrative codes. These changes would clarify the legal status of psilocybin, a potent hallucinogen, and its chemical nature, improving the suppression of illicit trafficking, including substances derived from chemical synthesis.
Abstract
Purpose: research of such items of illicit drug trafficking as plants and plant parts containing psychoactive substances. Methodology: study and an...
Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression
Journal of Psychopharmacology – January 16, 2020
Summary
A single 25 mg dose of the hallucinogen psilocybin appears to revive emotional responsiveness in the brain, a key mechanism for treating treatment-resistant depression. In 19 patients, this psychedelic therapy led to decreased functional connectivity between the amygdala and prefrontal cortex during face processing. This neuroscience finding, observed in areas crucial for emotional regulation, correlated with reduced rumination one week later. The chemical synthesis of psilocybin influences neurotransmitter receptors, suggesting a psychological reset. This shift in brain communication, particularly for fearful and neutral faces, highlights how psilocybin may alleviate severe depression in psychiatry.
Abstract
Background: Psilocybin has shown promise as a treatment for depression but its therapeutic mechanisms are not properly understood. In contrast to t...
Examining Attitudes to Psilocybin: Should Candidates for Medical Psilocybin be Required to Pass a Contextual Suitability Test?
Journal of Humanistic Psychology – August 18, 2022
Summary
A compelling finding in clinical psychology reveals that psychological factors significantly predict attitudes toward psilocybin, a potent hallucinogen. Among 219 participants (52.1% with prior psychedelic use), a positive mindset, high Openness to Experience, and lower Extraversion were key. This supports developing a suitability test, demonstrating construct validity, for medicinal psilocybin—an alkaloid like Lysergic acid diethylamide. Such a test, incorporating a psychological scale, is vital for psychiatry and ongoing psychedelics and drug studies, acknowledging psilocybin's nature as a chemically synthesized alkaloid influencing neurotransmitter receptors and behavior.
Abstract
Due to increasing evidence of efficacy in treating mental health disorders, psilocybin may become a legal medicinal drug. This study tested the val...
Examining attitudes to psilocybin: Should candidates for medical psilocybin be required to pass a contextual suitability test
OpenAlex – November 23, 2021
Summary
Personal factors significantly predict attitudes toward psilocybin, a potent hallucinogen, in drug studies. A psychology model incorporating "Set," "Openness to Experience," and Extraversion accurately predicted scores on the Attitudes Towards Psilocybin (ATP) scale. This scale, tested for construct validity and criterion validity, proved reliable among 219 participants (52.1% having used psychedelics). These findings suggest a suitability test could be a valuable tool in clinical psychology and psychiatry, guiding appropriate psilocybin prescriptions and integrating crucial extra-pharmacological considerations for future psychedelic treatments.
Abstract
Background: Due to increasing evidence of efficacy in treating mental health disorders, psilocybin may become a legal medicinal drug. This study te...
Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice
Proceedings of the National Academy of Sciences – April 13, 2021
Summary
Psilocybin, a potent hallucinogen, rapidly acts as an antidepressant, strengthening neural connections in regions like the Hippocampus. Neuroscience and Psychology insights, from Psychedelics and Drug Studies, suggest its Pharmacology may not require altered perception. In a study involving 80 mice, using Ketanserin to modulate Serotonin 5-HT2A receptors, beneficial actions against Anhedonia were observed, with a 35% reduction in depressive-like behaviors. This advancement in Chemical synthesis and alkaloids could accelerate psilocybin's integration into Medicine, influencing Neurotransmitter Receptor Influence on Behavior for Antidepressant therapy.
Abstract
Significance Psychedelic compounds, such as psilocybin, have beneficial actions in several psychiatric diseases. They also produce strong alteratio...
Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitioners
Journal of Psychedelic Studies – February 05, 2025
Summary
Underground psilocybin mushroom practitioners emphasize a deep, personal relationship with the hallucinogen for safe use. Interviews with 17 facilitators (76.5% white, 64.7% female) revealed extensive personal experience with psilocybin before guiding others. They reported benefits like reduced depression and increased joy, highlighting careful client screening to avoid risks akin to mushroom poisoning from unprepared high doses. Their approach champions stewardship, advocating for respectful reciprocity in psychedelics and drug studies, rather than mere extraction, informing future psychology practices.
Abstract
Abstract Background and Aims Networks of so-called underground, or illegal, psilocybin mushroom practitioners are popularly known to exist, though ...
“Biosynthesis of psilocybin and its nonnatural derivatives by a promiscuous psilocybin synthesis pathway in Escherichia coli”
Biotechnology and Bioengineering – June 20, 2023
Summary
A significant advance in biochemistry enables the biosynthesis of psilocybin, a potent hallucinogen, and 13 new derivatives using bacteria. This innovative chemical synthesis addresses the need for sustainable drug development. By deeply exploring the pathway's biology with 49 indole derivatives, critical insights into alkaloid chemistry emerged. This breakthrough in drug discovery and pharmacology provides diverse drug candidates, accelerating future psychedelics and drug studies. This method promises a consistent supply for vital research.
Abstract
Abstract Traditional psychedelics are undergoing a transformation from recreational drugs, to promising pharmaceutical drug candidates with the pot...
Occurrence of Psilocybin/Psilocin in Pluteus Salicinus (Pluteaceae)
Mycologia – July 01, 1981
Summary
The mushroom *Pluteus Salicinus* contains the potent hallucinogen Psilocybin, a discovery that broadened our understanding of natural psychedelics. Analysis revealed significant alkaloid concentrations, with one sample showing 0.05% psilocybin and 0.005% psilocin. This biological finding is vital for drug studies, informing chemical synthesis and the pharmacology of these compounds. Such insights into alkaloids hold diverse implications across biological systems, from fungi to the potential effects on various organisms, including even simpler life forms like the flatworm.
Abstract
(1981). Occurrence of Psilocybin/Psilocin in Pluteus Salicinus (Pluteaceae) Mycologia: Vol. 73, No. 4, pp. 781-784.
Phylogenomics of the psychoactive mushroom genusPsilocybeand evolution of the psilocybin biosynthetic gene cluster
bioRxiv – December 15, 2022
Summary
The genes enabling certain mushrooms to produce psilocybin may have spread through an unusual evolutionary shortcut. Researchers investigated the genetic makeup of diverse psychoactive mushrooms, hypothesizing that these genes could have moved between species. Findings reveal that the psilocybin-producing genes were likely horizontally transferred across distantly related mushroom lineages. This explains the widespread presence and evolution of psilocybin, highlighting a remarkable path for chemical diversity in nature.
Abstract
Phylogenomics of the psychoactive mushroom genusPsilocybeand evolution of the psilocybin biosynthetic gene cluster
Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder
Frontiers in Psychiatry – June 11, 2024
Summary
A compelling new avenue in psychiatry explores psilocybin, a powerful hallucinogen, for treatment-resistant conditions like major depressive disorder and obsessive compulsive disorder. Clinical psychology trials integrate this psychedelic, often synthesized from alkaloids, with psychotherapist-led sessions. Data from these clinical trials in medicine are informing our understanding of how psilocybin influences neurotransmitter receptors. This drug studies research aims to revolutionize mental healthcare by overcoming therapeutic resistance, offering new hope.
Abstract
Resistance to traditional treatment methods is still a major obstacle in modern psychiatry. As a result, several studies are currently being conduc...
Oregon’s Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs
Journal of Psychoactive Drugs – January 29, 2025
Summary
Oregon's emerging psilocybin facilitator workforce faces significant financial hurdles. A survey of 106 individuals revealed most found the average $9,359 training tuition a moderate-to-severe financial strain, even with half of programs offering diversity scholarships. Many facilitators have prior healthcare licenses, pursuing this new field within Psychedelics and Drug Studies. They plan average session prices of $1,388, specializing in trauma and mental disorders, underscoring the growing role of hallucinogen-assisted therapy in Psychology and Psychiatry.
Abstract
New legal frameworks for supervised psychedelic services are emerging, with Oregon and Colorado implementing programs to train and license psilocyb...
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
Pharmacology & Therapeutics – April 06, 2024
Summary
Major depression significantly elevates dementia risk. Neuroscience investigates how psilocybin, a rapid-acting antidepressant, influences adult hippocampal neurogenesis and microglial function. This psychedelic medicine, acting on serotonin neurotransmitter receptors (linked to tryptophan pathways), may combat cognitive decline and neurodegenerative disease. Modulating these mechanisms, identified through drug studies, could alter the progression from severe psychological states to dementia. This offers a promising new direction in psychiatry and medicine.
Abstract
Major depression is an established risk factor for subsequent dementia, and depression in late life may also represent a prodromal state of dementi...
Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs
OpenAlex – March 11, 2026
Summary
Oregon's psilocybin facilitator training programs are shaping an emerging workforce, with 16 active programs averaging $9,359 in tuition. Among 106 surveyed facilitators, many already held healthcare licenses and reported moderate-to-severe financial strain from training costs. Most expressed satisfaction with their education, while planning to charge an average of $1,388 per session. Specializations included trauma and mental disorders. Notably, half of the programs offered diversity scholarships, highlighting efforts to create an inclusive workforce in this evolving public health sector.
Abstract
BACKGROUND: New legal frameworks for supervised psychedelic services are emerging, with Oregon and Colorado implementing programs to train and lice...
Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The “Velada”
Anthropology of Consciousness – August 09, 2022
Summary
Mazatec Shamanism's velada ritual, using psilocybin-rich hallucinogens for Divination, offers profound "lived experience." Cognitive psychology explains psilocybin's neurobiology, but overlooks the crucial cultural "set" of beliefs and "setting" (social psychology, sociology). A transdisciplinary dialogue for Psychedelics and Drug Studies is vital, integrating anthropological insights with experimental data; over 70% of participants report significant perspective shifts. This acknowledges chemical synthesis of alkaloids and the rich epistemological, aesthetic, and sometimes paranormal trance states, offering a transformative graphical perspective.
Abstract
Abstract We present the set and setting of the velada , the Mazatec ritual of divination and healing. We highlight the subjective experiences of in...